MA51999A - Nouvelle formulation pharmaceutique comprenant des antagonistes doubles des récepteurs nk-1/nk-3 - Google Patents

Nouvelle formulation pharmaceutique comprenant des antagonistes doubles des récepteurs nk-1/nk-3

Info

Publication number
MA51999A
MA51999A MA051999A MA51999A MA51999A MA 51999 A MA51999 A MA 51999A MA 051999 A MA051999 A MA 051999A MA 51999 A MA51999 A MA 51999A MA 51999 A MA51999 A MA 51999A
Authority
MA
Morocco
Prior art keywords
receptor
pharmaceutical formulation
formulation including
new pharmaceutical
including dual
Prior art date
Application number
MA051999A
Other languages
English (en)
Other versions
MA51999B1 (fr
Inventor
Derek Bush
David Elder
Mary Kerr
Monica Lazaro
Mike Trower
Original Assignee
Kandy Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65817992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA51999(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kandy Therapeutics Ltd filed Critical Kandy Therapeutics Ltd
Publication of MA51999A publication Critical patent/MA51999A/fr
Publication of MA51999B1 publication Critical patent/MA51999B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA51999A 2018-03-14 2019-03-13 Nouvelle formulation pharmaceutique comprenant deux antagonistes recepteurs de nk-1/nk-3. MA51999B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862642622P 2018-03-14 2018-03-14
PCT/EP2019/056303 WO2019175253A1 (fr) 2018-03-14 2019-03-13 Nouvelle formulation pharmaceutique comprenant des antagonistes doubles des récepteurs nk-1/nk-3

Publications (2)

Publication Number Publication Date
MA51999A true MA51999A (fr) 2021-01-20
MA51999B1 MA51999B1 (fr) 2024-02-29

Family

ID=65817992

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51999A MA51999B1 (fr) 2018-03-14 2019-03-13 Nouvelle formulation pharmaceutique comprenant deux antagonistes recepteurs de nk-1/nk-3.

Country Status (34)

Country Link
US (6) US10774091B2 (fr)
EP (1) EP3765024B1 (fr)
JP (1) JP7433252B2 (fr)
KR (1) KR102833016B1 (fr)
CN (2) CN112292132A (fr)
AU (1) AU2019233606B2 (fr)
CA (1) CA3092238A1 (fr)
CL (1) CL2020002350A1 (fr)
CO (1) CO2020011262A2 (fr)
CR (1) CR20200385A (fr)
DK (1) DK3765024T3 (fr)
EA (1) EA202092131A1 (fr)
EC (1) ECSP20057488A (fr)
ES (1) ES2974300T3 (fr)
FI (1) FI3765024T3 (fr)
GE (2) GEAP202215464A (fr)
HR (1) HRP20240120T1 (fr)
HU (1) HUE065300T2 (fr)
IL (1) IL276959B2 (fr)
JO (1) JOP20200227B1 (fr)
LT (1) LT3765024T (fr)
MA (1) MA51999B1 (fr)
MX (2) MX392190B (fr)
MY (1) MY201590A (fr)
PE (1) PE20210395A1 (fr)
PH (1) PH12020551457A1 (fr)
PL (1) PL3765024T3 (fr)
PT (1) PT3765024T (fr)
RS (1) RS65257B1 (fr)
SA (1) SA520420126B1 (fr)
SG (1) SG11202008226YA (fr)
SI (1) SI3765024T1 (fr)
UA (1) UA128159C2 (fr)
WO (1) WO2019175253A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016264034B2 (en) * 2015-05-18 2020-03-05 KaNDy Therapeutics Limited Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EP3512839A4 (fr) 2016-09-18 2020-03-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibiteurs de yap1 ciblant l'interaction de yap1 avec oct4
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
WO2019178401A1 (fr) 2018-03-14 2019-09-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibiteurs de yap1 ciblant l'interaction de yap1 avec oct4
EP4058433A1 (fr) 2019-11-15 2022-09-21 KaNDy Therapeutics Limited Nouveau procédé chimique de préparation de 6-chloro-4-(4-fluoro-2-méthylphényl)pyridin-3-amine, un intermédiaire clé de nt-814
CA3168199A1 (fr) * 2020-02-19 2021-08-26 Eri ICHIBAYASHI Preparation a absorption transdermique
KR102484687B1 (ko) * 2022-03-04 2023-01-05 (주)씨앤엘디 페노피브레이트를 포함하는 이상지질혈증의 예방 또는 치료용 약학 조성물
WO2025242584A1 (fr) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Formulation de capsule de gélatine molle stable pour élinzanétant
WO2025242585A1 (fr) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Formes cristallines de sels d'élinzanétant et compositions contenant des sels d'élinzanétant
WO2025242583A1 (fr) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Nouvelle formulation comprenant de l'élinzanétant dans une dispersion solide
US12533358B1 (en) 2025-05-14 2026-01-27 Bayer Consumer Care Ag Methods of treatment with elinzanetant

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3097618A (en) 1960-12-01 1963-07-16 Raymond Bag Corp Manufacture of multi-wall bag having heat-sealed liner
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
WO1996003138A1 (fr) 1994-07-22 1996-02-08 The Medical College Of Hampton Roads Procede pour assurer une secretion tonique d'oestrogene ovarien dans des regimes therapeutiques de longue duree
DE60018707T2 (de) 1999-01-25 2006-02-09 Smithkline Beecham Corp. Anti-androgene und verfahren zur behandlung von krankheiten
GB9907571D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Compounds
WO2001095904A1 (fr) 2000-06-12 2001-12-20 University Of Rochester Methode de traitement de symptomes de la variation hormonale, tels que les bouffees de chaleur, au moyen d'un antagoniste du recepteur de la tachykinine
EP1192952A3 (fr) 2000-09-28 2003-03-26 Pfizer Products Inc. Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
WO2002089802A2 (fr) 2001-05-08 2002-11-14 Schering Corporation Utilisation d'antagonistes de recepteur de neurokinine pour le traitement de maladies liees aux androgenes
OA12619A (en) 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
JP4677235B2 (ja) 2002-12-23 2011-04-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換４−（４−ピペリジン−４−イル−ピペラジン−１−イル）−アゼパン誘導体およびそれらのニューロキニン拮抗薬としての使用
US7525659B2 (en) 2003-01-15 2009-04-28 Negevtech Ltd. System for detection of water defects
ES2291891T3 (es) 2003-07-03 2008-03-01 F. Hoffmann-La Roche Ag Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.
JO2676B1 (en) 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2525B1 (en) 2004-04-08 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
JP2007537233A (ja) 2004-05-12 2007-12-20 ファイザー・プロダクツ・インク Ｎｋ１及びｎｋ３アンタゴニストとしてのピペリジン誘導体
DE102004033902A1 (de) 2004-07-14 2006-02-16 Zentaris Gmbh Neue Tetrahydrocarbazolderivate mit verbesserter biologischer Wirkung und verbesserter Löslichkeit als Liganden für G-Protein gekoppelte Rezeptoren (GPCR's)
WO2006013205A1 (fr) 2004-08-04 2006-02-09 Solvay Pharmaceuticals B.V. Antagonistes des récepteurs de la neurokinine-1 pour le traitement des états sensibles à une élévation de la testostérone
US20060030600A1 (en) 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
DK1928886T3 (da) 2005-09-09 2011-07-11 Glaxosmithkline Llc Pyridin-derivater og deres anvendelse i behandlingen af psykotiske lidelser
JP2010502703A (ja) 2006-09-06 2010-01-28 メルク エンド カムパニー インコーポレーテッド 置換アミドの経口投与のための液体及び半固体の医薬製剤
DE602008001983D1 (de) 2007-04-20 2010-09-09 Hoffmann La Roche Pyrrolidinderivate als doppelte nk1/nk3-rezeptorenantagonisten
GB0814340D0 (en) 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
ES2440938T3 (es) 2009-08-27 2014-01-31 Nerre Therapeutics Limited Formas anhidrato de un derivado de piridina
US8487102B2 (en) 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US9446029B2 (en) 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
ES2376564B1 (es) 2010-08-12 2013-01-24 Manuel Vicente Salinas Martín Utilización de anticuerpos contra los receptores nk1, nk2 y/o nk3, para producir apoptosis en las células tumorales y modificar el estroma, la inmunidad y la vascularización intra y peritumorales, como tratamiento del cáncer.
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
SG11201402689XA (en) 2011-12-02 2014-06-27 Glaxosmithkline Ip No 2 Ltd Peptide deformylase inhibitors
KR101739820B1 (ko) 2012-03-28 2017-05-25 주식회사유한양행 레바프라잔 또는 그의 염을 함유하는 비수성 액체 형태의 경구투여용 약학 조성물
US20130302414A1 (en) 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
US20150272927A1 (en) 2012-12-03 2015-10-01 University Of Washington Through Its Center For Commercialization Methods and compositions for treating vasomotor symptoms
JP6316932B2 (ja) 2013-03-29 2018-04-25 オゲダ エス．エー． 選択的ＮＫ−３受容体拮抗薬としての新規なＮ−アシル−（３位置換）−（８位置換）−５，６−ジヒドロ−［１，２，４］トリアゾロ［４，３−ａ］ピラジン、医薬組成物、ＮＫ−３受容体媒介性障害における使用方法
GB201315846D0 (en) 2013-09-05 2013-10-23 Imp Innovations Ltd Method for treating or preventing hot flushes
AU2016264034B2 (en) 2015-05-18 2020-03-05 KaNDy Therapeutics Limited Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
EA202092131A1 (ru) 2018-03-14 2020-11-27 Кэнди Терапьютикс Лимитед Новый фармацевтический препарат, содержащий двойные антагонисты рецептора nk-1/nk-3
EP4058433A1 (fr) 2019-11-15 2022-09-21 KaNDy Therapeutics Limited Nouveau procédé chimique de préparation de 6-chloro-4-(4-fluoro-2-méthylphényl)pyridin-3-amine, un intermédiaire clé de nt-814

Also Published As

Publication number Publication date
IL276959B1 (en) 2024-03-01
EA202092131A1 (ru) 2020-11-27
AU2019233606B2 (en) 2024-10-03
SG11202008226YA (en) 2020-09-29
CR20200385A (es) 2021-05-21
MX2020009438A (es) 2022-05-11
JOP20200227B1 (ar) 2024-04-18
SA520420126B1 (ar) 2024-02-01
FI3765024T3 (fi) 2024-02-14
HRP20240120T1 (hr) 2024-04-12
PT3765024T (pt) 2024-02-19
KR102833016B1 (ko) 2025-07-14
JOP20200227A1 (ar) 2020-09-13
US20190284205A1 (en) 2019-09-19
US20230382922A1 (en) 2023-11-30
DK3765024T3 (da) 2024-02-12
CN112292132A (zh) 2021-01-29
MX392190B (es) 2025-03-21
LT3765024T (lt) 2024-02-26
US11767328B2 (en) 2023-09-26
US20200361956A1 (en) 2020-11-19
HUE065300T2 (hu) 2024-05-28
JP7433252B2 (ja) 2024-02-19
US10774091B2 (en) 2020-09-15
MA51999B1 (fr) 2024-02-29
MY201590A (en) 2024-03-04
UA128159C2 (uk) 2024-04-24
US12264164B2 (en) 2025-04-01
CL2020002350A1 (es) 2021-04-16
RS65257B1 (sr) 2024-03-29
AU2019233606A1 (en) 2020-09-17
JP2021517590A (ja) 2021-07-26
US11591346B2 (en) 2023-02-28
ES2974300T3 (es) 2024-06-26
EP3765024B1 (fr) 2023-11-22
IL276959A (en) 2020-10-29
US20230174552A1 (en) 2023-06-08
NZ767340A (en) 2025-11-28
KR20200139138A (ko) 2020-12-11
SI3765024T1 (sl) 2024-05-31
CN119950513A (zh) 2025-05-09
PL3765024T3 (pl) 2024-08-05
MX2022005706A (es) 2022-06-08
CA3092238A1 (fr) 2019-09-19
US11787820B2 (en) 2023-10-17
GEP20237503B (en) 2023-04-25
PH12020551457A1 (en) 2021-11-22
EP3765024A1 (fr) 2021-01-20
IL276959B2 (en) 2024-07-01
GEAP202215464A (en) 2022-11-25
CO2020011262A2 (es) 2020-12-10
ECSP20057488A (es) 2020-12-31
WO2019175253A1 (fr) 2019-09-19
US20200361957A1 (en) 2020-11-19
US20250154167A1 (en) 2025-05-15
BR112020017388A2 (pt) 2020-12-15
PE20210395A1 (es) 2021-03-02

Similar Documents

Publication Publication Date Title
IL276959A (en) A new pharmaceutical formulation containing dual NK-1/NK-3 receptor antagonists
EP3881846A4 (fr) Composition pharmaceutique comprenant des inhibiteurs de parp
IL279464A (en) Pharmaceutical formulation of odevixibat
MA47816A (fr) Composition pharmaceutique comprenant du sélexipag
NI201600152A (es) Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4
MA49879A (fr) Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
EA201692356A1 (ru) Гидрохлоридные соли n-(цианометил)-4-(2-(4-морфолинофениламино)пиримидин-4-ил)бензамида
EA201692433A1 (ru) Соединения ppar для применения при лечении фиброзных заболеваний
MX377052B (es) Antagonistas duales de receptores de neurocinina-1 (nk-1) / neurocinina-3 (nk-3) para el tratamiento de enfermedades dependientes de hormonas sexuales.
EP3452075A4 (fr) Composition pharmaceutique ophtalmique
EP3348260A4 (fr) Composition pharmaceutique de tramadol destinée à un usage ophthalmique
LT3713928T (lt) Nauji bradikinino b2 receptoriaus antagonistai
DK3634377T3 (da) Farmaceutisk formulering
HUE063043T2 (hu) Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására
DK3303323T3 (da) Heterocykliske forbindelser af 3,3-difluorpiperidincarbamat som NR2B-NMDA-receptorantagonister
EP3836921C0 (fr) Compositions pharmaceutiques liquides de bendamustine
IL280047A (en) Formulation of cannabinoid compounds
EA201890156A1 (ru) Антагонисты рецептора cgrp
EP3697781C0 (fr) Antagonistes du récepteur muscarinique de l'acétylcholine m4
MA53466A (fr) Formulation stable d'anticorps anti-osmr
EP3582759A4 (fr) Composition pharmaceutique bioéquivalente de bromhydrate de vortioxétine
PH12016501625A1 (en) Substituted cyclopentanes, tetrahydrofuranes and pyrrolidines as orexin receptor antagonists
EP3946296A4 (fr) Formulation pharmaceutique à libération prolongée
EP3795166A4 (fr) Composition pharmaceutique d'agoniste du récepteur kor
EP3705122A4 (fr) Composition pharmaceutique à libération prolongée